Holen Sie sich die Stockscreener-App
10.61
3.50%
-0.38
Schlusskurs vom Vortag:
$10.98
Offen:
$11.13
24-Stunden-Volumen:
172.34K
Relative Volume:
0.14
Marktkapitalisierung:
$928.35M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-185.15M
KGV:
-5.2363
EPS:
-2.0253
Netto-Cashflow:
$-148.72M
1W Leistung:
-2.12%
1M Leistung:
-12.03%
6M Leistung:
-33.75%
1J Leistung:
+42.47%
1-Tages-Spanne:
$10.59
$11.18
1-Wochen-Bereich:
$10.46
$11.18
52-Wochen-Spanne:
$6.65
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Firmenname
Olema Pharmaceuticals Inc
Sektor
Branche
Telefon
(415) 651-3316
Adresse
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
10.61 | 961.16M | 0 | -185.15M | -148.72M | -2.0253 |
VRTX
Vertex Pharmaceuticals Inc
|
522.74 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.43 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,005.05 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.68 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.07 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-03-19 | Fortgesetzt | Jefferies | Buy |
| 2026-02-11 | Eingeleitet | Stifel | Buy |
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-08 | Eingeleitet | Guggenheim | Buy |
| 2025-08-12 | Bestätigt | Citigroup | Buy |
| 2024-04-02 | Eingeleitet | Goldman | Buy |
| 2024-01-30 | Eingeleitet | Citigroup | Buy |
| 2023-07-21 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-05 | Eingeleitet | CapitalOne | Overweight |
| 2023-02-22 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-12-14 | Eingeleitet | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Olema Pharmaceuticals Inc Aktie (OLMA) Neueste Nachrichten
Wellington Management Group LLP Cuts Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Readystate Asset Management LP Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Bank of New York Mellon Corp Invests $2.78 Million in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
OLMA Sees Early Tumor Shrinkage in Phase 1 OP-3136 Study, Stock Gains Pre-Market - Stocktwits
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Olema Pharmaceuticals Grants Inducement Stock Options to Newly Appointed CFO Jason V. O’Byrne - Quiver Quantitative
Olema Pharmaceuticals (NASDAQ: OLMA) grants CFO 650K options expiring in 2036 - Stock Titan
Olema Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire
Olema Oncology will join three investor conferences in New York this September - Stock Titan
BlackRock Inc. Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals Inc. (OLMA) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Olema Pharmaceuticals Inc. (OLMA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Jupiter Topco LLC Takes $88.80 Million Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Bank of America Corp DE Raises Stock Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Olema Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:OLMA) - MarketBeat
OLMA News | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Olema Oncology appoints Jason O’Byrne as CFO - The Pharma Letter
OLMA Maintained by JP Morgan -- Price Target Lowered to $46.00 - GuruFocus
JPMorgan Chase & Co. Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price - MarketBeat
Olema Pharmaceuticals, Inc. Announces Appointment of Jason O?Byrne to Chief Financial Officer, Effective August 11, 2026 - marketscreener.com
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Announces Target Price $46 - moomoo.com
Olema Pharmaceuticals Names Jason O'Byrne as New CFO with Comprehensive Compensation Package - Kalkine Media
Form 8K Olema Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Nigeria
HC Wainwright Brokers Decrease Earnings Estimates for OLMA - MarketBeat
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer - The Manila Times
Olema Oncology’s New CFO Brings More Than Two Decades in Biotech - Stock Titan
Olema Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Harmon Cyrus - Moomoo
Olema stock falls 12.9% as Q2 loss widens to $63.2M on R&D spend - scanx.trade
OLMA Maintains Rating by Citigroup -- Price Target Lowered to $5 - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Lowered to $59.00 at Citigroup - MarketBeat
Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027 - TradingView
TD Cowen Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating - Moomoo
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Down on Disappointing Earnings - MarketBeat
Olema Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $39.9, Implies 234% Upside - TradingView
OLMA Maintains Buy Rating -- Price Target Lowered to $36.00 by H - GuruFocus
H.C. Wainwright lowers Olema Pharmaceuticals price target to $36 By Investing.com - Investing.com Canada
Olema Pharmaceuticals Q2 Loss Widens - marketscreener.com
Earnings Flash (OLMA) Olema Pharmaceuticals Posts Q2 Loss per Share $0.61, vs. FactSet Est of $0.55 Loss - marketscreener.com
Olema Oncology (OLMA) Advances Phase 3 Trial Enrollment Amid Mixed Market Signals - GuruFocus
Olema Pharmaceuticals falls 6% on second quarter EPS miss By Investing.com - Investing.com Canada
Olema Pharmaceuticals falls 6% on second quarter EPS miss - Investing.com
Olema Pharmaceuticals (NASDAQ:OLMA) Releases Earnings Results, Misses Estimates By $0.08 EPS - MarketBeat
Olema Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Olema Pharmaceuticals (OLMA) widens net loss but ends Q2 2026 with $461M in cash - Stock Titan
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results - Yahoo Finance
Olema Pharmaceuticals earnings up next ahead of key trial data By Investing.com - Investing.com Canada
Olema Pharmaceuticals earnings up next ahead of key trial data - Investing.com
Dimensional Fund Advisors LP Acquires 123,790 Shares of Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
FMR LLC, Abigail Johnson disclose 13.8% Olema Pharmaceuticals (OLMA) ownership - Stock Titan
Finanzdaten der Olema Pharmaceuticals Inc-Aktie (OLMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):